Adult: During the puerperium: 0.2 mg 3 or 4 times daily for 1 week.
Parenteral Postpartum haemorrhage
Adult: After delivery of the anterior shoulder or placenta, or during the puerperium: 0.2 mg via IM inj. Doses may be repeated every 2-4 hours as necessary. In emergencies, the same dose may be given via slow IV infusion over 1 minute.
Monitor blood pressure, CNS status, and vaginal bleeding.
Symptoms: Nausea, vomiting, abdominal pain, oliguria, tingling of the extremities, high blood pressure; hypotension, respiratory depression, hypothermia, convulsions. Management: Symptomatic and supportive treatment. Remove offending drug by inducing emesis, gastric lavage, catharsis, or supportive diuresis. Maintain adequate pulmonary ventilation, especially if convulsion or coma develop. Use standard anticonvulsant agents to control convulsion. Correct hypotension with pressor drugs. Treat peripheral vasospasm by applying warmth to the extremities as necessary.
Increased risk of ergot toxicity with CYP3A4 inhibitors (e.g. erythromycin, clarithromycin, ritonavir, delavirdine, ketoconazole, itraconazole, voriconazole). Enhance vasoconstrictive effect with β-blockers. Diminished therapeutic effect with anaesthetics (e.g. halothane, methoxyflurane). Reduced therapeutic effect of glyceryl trinitrate and other antianginal medications.
Description: Methylergometrine is an ergot alkaloid. It increases the tone, rate and amplitude of uterine contractions which shortens the third stage of labour and reduces blood loss.
Synonym: methylergonovine. Onset: 5-10 minutes (oral); 2-5 minutes (IM). Duration: Approx 3 hours (oral/IM). Pharmacokinetics: Absorption: Rapidly absorbed. Bioavailability: 60% (oral); 78% (IM). Time to peak plasma concentration: 0.3-2 hours (oral); 0.2-0.6 hours (IM). Distribution: Enters breast milk. Volume of distribution: 39-73 L. Metabolism: Undergoes extensive first-pass hepatic metabolism. Excretion: Via the urine and faeces. Elimination half-life: Approx 3 hours.
Tab: Store between 20-25°C. Inj: Store between 2-8°C. Protect from light.
G02AB01 - methylergometrine ; Belongs to the class of ergot alkaloids. Used to induce abortion or augment labour and to minimize blood loss from the placental site.
Anon. Methylergonovine. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 02/09/2020.Anon. Methylergonovine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 02/09/2020.Buckingham R (ed). Methylergometrine Maleate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 02/09/2020.Methylergonovine Maleate Injection (Breckenridge Pharmaceuticals, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 02/09/2020.Methylergonovine Tablet (Amneal Pharmaceuticals NY LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 02/09/2020.Methylergonovine. Gold Standard Drug Database in ClinicalKey [online]. Elsevier Inc. https://www.clinicalkey.com/. Accessed 02/09/2020.